stella
beta
A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation — Stella
Recruiting
Back to Non-Small Cell Lung Cancer trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(5 sites)
China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Peking Union Medical College Hospital, Beijing
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
Henan Provincial Cancer Hospital, Zhengzhou
Henan Provincial People's Hospital, Zhengzhou
View full record on ClinicalTrials.gov